(Q37924869)

25 August 2017

1 reference

title

Drug interactions with mitotane by induction of CYP3A4 metabolism in the clinical management of adrenocortical carcinoma (English)

1 reference

25 August 2017

2

Marcus Quinkler

1 reference

25 August 2017

Matthias Kroiss

1

1 reference

25 August 2017

Werner K Lutz

series ordinal

3

1 reference

25 August 2017

Bruno Allolio

series ordinal

4

1 reference

25 August 2017

Martin Fassnacht

series ordinal

5

1 reference

25 August 2017

publication date

1 November 2011

1 reference

25 August 2017

published in

Clinical Endocrinology

1 reference

25 August 2017

volume

75

1 reference

25 August 2017

issue

5

1 reference

25 August 2017

page(s)

585-591

1 reference

Adrenocortical carcinoma: a clinician's update

25 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2011.04214.X

Adjuvant mitotane treatment for adrenocortical carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2011.04214.X

Mitotane has a strong and a durable inducing effect on CYP3A4 activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2011.04214.X

Marginal increase of sunitinib exposure by grapefruit juice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2011.04214.X

VI. Biochemical and pathological effects. Organochlorine insecticides and the stimulation of liver microsome enzymes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2011.04214.X

Transcriptional induction of CYP3A4 by o,p'-DDT in HepG2 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2011.04214.X

Pregnane X receptor-dependent induction of the CYP3A4 gene by o,p'-1,1,1,-trichloro-2,2-bis (p-chlorophenyl)ethane

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2011.04214.X

The environmental pollutant 1,1-dichloro-2,2-bis (p-chlorophenyl)ethylene induces rat hepatic cytochrome P450 2B and 3A expression through the constitutive androstane receptor and pregnane X receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2011.04214.X

Effects of o,p'-DDD on cortisol and 6-beta-hydroxycortisol secretion and metabolism in man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2011.04214.X

Effect of o,p'-DDD on cortisol secretory pattern in Cushing's syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2011.04214.X

AN EFFECT OF O,P'-DDD ON THE EXTRA-ADRENAL METABOLISM OF CORTISOL IN MAN.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2011.04214.X

The effect of 2,2-bis (2-chlorophenyl-4-chlorophenyl)-1,1-dichloroethane (o,p'-DDD) on the metabolism of infused cortisol-7-3H.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2011.04214.X

EFFECT OF DIPHENYLHYDANTOIN ON CORTISOL METABOLISM IN MAN.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2011.04214.X

Quantification of cortisol and 6 beta-hydroxycortisol in human urine by LC-MS/MS, and gender-specific evaluation of the metabolic ratio as biomarker of CYP3A activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2011.04214.X

Polychlorinated biphenyl (PCB) induction of CYP3A4 enzyme activity in healthy Faroese adults.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2011.04214.X

Assessment of serum-free cortisol levels in patients with adrenocortical carcinoma treated with mitotane: a pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2011.04214.X

The effect of o,p'-DDD on adrenal steroid replacement therapy requirements

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2011.04214.X

Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2011.04214.X

Cytochromes P450 and metabolism of xenobiotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2011.04214.X

Antipyrine metabolite kinetics in healthy human volunteers during multiple dosing of phenytoin and carbamazepine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2011.04214.X

The effect of dexamethasone on the pharmacokinetics of triazolam.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2011.04214.X

Effect of phenobarbitone on hepatic drug-metabolizing enzymes and urinary D-glucaric acid excretion in man

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2011.04214.X

Comparative effects of thiazolidinediones on in vitro P450 enzyme induction and inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2011.04214.X

Reduced plasma nisoldipine concentrations in phenytoin-treated patients with epilepsy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2011.04214.X

Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2011.04214.X

Effect of the treatment period with erythromycin on cytochrome P450 3A activity in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2011.04214.X

Ketoconazole and fluconazole drug interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2011.04214.X

Effects of the antifungal agents on oxidative drug metabolism: clinical relevance

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2011.04214.X

Interaction of Azoles with Rifampin, Phenytoin, and Carbamazepine: In Vitro and Clinical Observations

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2011.04214.X

The effects of ketoconazole on the intestinal metabolism and bioavailability of cyclosporine*

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2011.04214.X

Steroid biosynthesis inhibitors in the therapy of hypercortisolism: theory and practice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2011.04214.X

Crystal structures of human cytochrome P450 3A4 bound to metyrapone and progesterone

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2011.04214.X

Hydroxylation of warfarin by human cDNA-expressed cytochrome P-450: a role for P-4502C9 in the etiology of (S)-warfarin-drug interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2011.04214.X

Etoposide, doxorubicin and cisplatin plus mitotane in the treatment of advanced adrenocortical carcinoma: a large prospective phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2011.04214.X

Streptozocin and o,p'DDD in the treatment of adrenocortical cancer patients: long-term survival in its adjuvant use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2011.04214.X

Mitotane Enhances Cytotoxicity of Chemotherapy in Cell Lines Expressing a Multidrug Resistance Gene (mdr-1/P-Glycoprotein) which is also Expressed by Adrenocortical Carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2011.04214.X

A phase II trial of combination chemotherapy and surgical resection for the treatment of metastatic adrenocortical carcinoma: continuous infusion doxorubicin, vincristine, and etoposide with daily mitotane as a P-glycoprotein antagonist.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2011.04214.X

Gemcitabine plus metronomic 5-fluorouracil or capecitabine as a second-/third-line chemotherapy in advanced adrenocortical carcinoma: a multicenter phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2011.04214.X

New targets and therapeutic approaches for endocrine malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2011.04214.X

Treatment of advanced adrenocortical carcinoma with erlotinib plus gemcitabine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2011.04214.X

Clinical pharmacokinetics of tyrosine kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2011.04214.X

Metabolism considerations for kinase inhibitors in cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2011.04214.X

Alprazolam is another substrate for human cytochrome P450-3A isoforms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2011.04214.X

Regioselective biotransformation of midazolam by members of the human cytochrome P450 3A (CYP3A) subfamily.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2011.04214.X

Drug interactions with the taxanes: clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2011.04214.X

5-Fluorouracil, doxorubicin, and cisplatin as treatment for adrenal cortical carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2011.04214.X

10.1111/J.1365-2265.2011.04214.X

21 January 2018

Identifiers

DOI

1 reference

25 August 2017

1 reference